首页 | 本学科首页   官方微博 | 高级检索  
检索        

重组人生长激素治疗特发性身材矮小患儿的疗效评价
引用本文:李欣,史轶蘩.重组人生长激素治疗特发性身材矮小患儿的疗效评价[J].中国医院用药评价与分析,2005,5(1):15-18.
作者姓名:李欣  史轶蘩
作者单位:中国医学科学院北京协和医院内分泌科,北京市,100730
摘    要:目的:重组人生长激素(rhGH)为基因工程大肠杆菌或哺乳动物细胞产生的人生长激素,其结构和氨基酸排序与人垂体激素雷同,本文评价其治疗特发性身体矮小患者的疗效与安全性.方法:查阅国内外近期相关文献,并结合笔者临床经验进行综述.结果与结论:尽管疗效研究组为重组人生长激素可改善特发性身材矮小患儿的最终身高,但临床上尚有争议,尤其是诊断内源性生长激素缺乏仍是尚待突破的课题.

关 键 词:重组人生长激素  特发性身材矮小  最佳治疗方案  争议
文章编号:1672-2124(2005)01-0015-04
修稿时间:2004年11月30

Evaluation of Curative Effect of Human Growth Hormone Recombinant(rhGH) on Idiopathic Microsomia Children
LI Xin,SHI Yifan.Evaluation of Curative Effect of Human Growth Hormone Recombinant(rhGH) on Idiopathic Microsomia Children[J].Evaluation and Analysis of Drug-Use in Hospital of China,2005,5(1):15-18.
Authors:LI Xin  SHI Yifan
Abstract:OBJECTIVE:rhGH is human growth hormone produced by Bacillus coli or mammalian cells of gene engineering. Its structure and amino acid rank are similar to that of human pituitary hormone. This paper is to evaluate curative effect and the safety of rhGH on idiopathic microsomia children. METHODS: By looking up recent literatures at home and abroad and connecting our clinical experience to make a review. RESULTS & CONCLUSION: Although research group considers rhGH may improve the final body height of idiopathic microsomia children, there still exist some controversy in the clinic, especially, diagnosis of endogenous growth hormone deficiency is still an important topic to be broken through.
Keywords:human growth hormone recombinant(rhGH)  idiopathic microsomia  best therapeutic regimen  controversy
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号